Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC

Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing... Read More

Optimal therapy for high-risk localized prostate cancer remains unclear

Among the many approaches and treatment combinations available for men with high-risk localized prostate cancer, the optimal strategy remains to... Read More

ASCO Issues New Guidelines for Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer

The American Society of Clinical Oncology (ASCO) has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy (ADT)... Read More

First-Line Docetaxel Improves QoL, Proves Cost-Effective in Prostate Cancer

The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the... Read More

Focal Therapy for Primary Localized Prostate Cancer Remains Investigational

Focal therapy for primary localized prostate cancer should remain investigational pending further study, according to a 2018 European Association of... Read More

Biopsies Often Not Useful 2 Years After Radiotherapy for Prostate Cancer

Two-year post-radiotherapy biopsies do not predict survival for most men with prostate cancer, according to results from the RT01 trial.... Read More